Evidence & regulatory context
- Mechanism
- ChEMBL NOT QUERIED: proprietary lipid nanoemulsion formulation, not a defined chemical entity; resolved=false by entity class. DELIBERATE ZERO-TRIAL DECISION, explicitly searched not assumed: CTgov intervention query 'hyperosmotic nanoemulsion OR hypertonic saline nanoemulsion' returned 0 records.
- Target
- Not recorded
- Injury models
- Wound
- Reported indication
- Not recorded
- First approval
- Not recorded
- Development stage
- Not recorded
- ChEMBL record
- Not recorded
- ChEMBL max phase
- Not recorded
- Synonyms
- Not recorded
- Note
- Not recorded
Clinical trials 0
0 linked trials carry an injury-indication flag. These flags support record-level exploration and sit alongside the stringent aggregate counts described in Methods.
No linked human trial in this dataset.
Preclinical evidence 1
1 studies reported at therapy level; 1 evidence entries itemised.
Guinea pigWoundFemaleTopicalAfter wounding and inoculation
Model: Full-thickness biopsy wound inoculated with Escherichia coli and Enterococcus faecalis at 5 x 10^6 total CFU
HNE reduced bacterial burden by about 3 logs within 24 h and shortened wound closure to 7.6 plus or minus 0.2 days versus 10.2 plus or minus 0.4 days for silver sulfadiazine and 10.4 plus or minus 0.3 days for control.
Extraction: extract · Supplied extraction confidence: 0.75. Machine-extracted fields require source verification.
